Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update

PR Newswire - Wed Mar 29, 2023

-  Year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, expected to fund operations into mid-2025

-  NDA submission for etripamil in patients with PSVT expected for 3Q23

Read more at prnewswire.com

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).